209984-33-8

Basic information

• Product Name: CarbaMic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-Methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]aMino]-1-Methyl-2-oxoethyl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-Methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]aMino]-1-Methyl-2-oxoethyl]-, 1,1-diMethylethyl ester;Tert-butyl ((S)-1-(((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)amino)-1-oxopropan-2-yl)carbamate
• CAS NO: 209984-33-8
• Molecular Formula: C23H27N3O4
• Molecular Weight: 409.47818
• Mol File: 209984-33-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 706.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• PKA: 11.32±0.46(Predicted)
• CAS DataBase Reference: CarbaMic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-Methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]aMino]-1-Methyl-2-oxoethyl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-Methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]aMino]-1-Methyl-2-oxoethyl]-, 1,1-diMethylethyl ester(209984-33-8)
• EPA Substance Registry System: CarbaMic acid, [(1S)-2-[[(7S)-6,7-dihydro-5-Methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]aMino]-1-Methyl-2-oxoethyl]-, 1,1-diMethylethyl ester(209984-33-8)

Safety Data

• Hazardous Substances Data: 209984-33-8(Hazardous Substances Data)

Upstream product

• 209984-32-7 7-amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one hydrochloride 
• 15761-38-3 L-N-Boc-Ala 
• 213024-76-1 7-amino-5-methyl-5H-dibenzo[b,d]azepin-6(7H)-one hydrochloride 
• 365242-16-6 (S)-5-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 

Downstream Products

• 253324-50-4 7-(S)-(L-alaninyl)-amino-5-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one 

Relevant articles and documents

CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Polycyclic α-amino-ε-caprolactams and related compounds

Disclosed are polycyclic α-amino-ε-caprolactams and related compounds which are useful as synthetic intermediates in the preparation of inhibitors of β-amyloid peptide release and/or its synthesis.